Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Frequently asked questions
What sector does Medicus Pharma Ltd. Common Stock (MDCX) operate in?
Medicus Pharma Ltd. Common Stock belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is Medicus Pharma Ltd. Common Stock (MDCX) current stock price?
As of the latest data, Medicus Pharma Ltd. Common Stock stock price is $2.45, with a previous close of $2.51. Medicus Pharma Ltd. Common Stock lost -$0.06 in the last trading session, representing a -2.39% loss.
What is Medicus Pharma Ltd. Common Stock (MDCX) current market capitalization?
Medicus Pharma Ltd. Common Stock market cap is approximately 154.79 million.
What is Medicus Pharma Ltd. Common Stock (MDCX) Earnings Per Share (EPS)?
The trailing EPS is -$2.36, and the forward EPS is -$0.38.
What is Medicus Pharma Ltd. Common Stock (MDCX) EBITDA?
Medicus Pharma Ltd. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.29 million.
Does Medicus Pharma Ltd. Common Stock (MDCX) pay dividends?
No. Medicus Pharma Ltd. Common Stock does not pay a dividend.
What is Medicus Pharma Ltd. Common Stock (MDCX) beta (volatility) score?
Medicus Pharma Ltd. Common Stock has a beta of -0.481, indicating lower volatility than the overall market.
